コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 on of prior systemic therapy and presence of liver metastases.
2 ncer, both CVX-060 and regorafenib inhibited liver metastases.
3 ic tumors and to accelerate the formation of liver metastases.
4 h as hepatocellular carcinoma and colorectal liver metastases.
5 dict response to neoadjuvant chemotherapy in liver metastases.
6 and a potential target for interference with liver metastases.
7 t detection of bone lesions, lymph node, and liver metastases.
8 nagement strategies exist for neuroendocrine liver metastases.
9 of two primary CRC tumors and their matched liver metastases.
10 le toxicity profile in salvage patients with liver metastases.
11 ase recurrence after resection of colorectal liver metastases.
12 n bile ducts induced cholangiocarcinoma with liver metastases.
13 as performed in mice bearing patient-derived liver metastases.
14 eight fresh human colorectal carcinoma (CRC) liver metastases.
15 portantly, ADPh prevented the development of liver metastases.
16 y, for the detection and characterization of liver metastases.
17 patients also had synchronous resections of liver metastases.
18 ents with colorectal cancer with synchronous liver metastases.
19 fibroblasts associated with human colorectal liver metastases.
20 e quality and in the detection of colorectal liver metastases.
21 ic lineages of two CRC patients with matched liver metastases.
22 that obtained after resection of colorectal liver metastases.
23 on 538 to glycine (D538G), was identified in liver metastases.
24 for salvage patients with colorectal cancer liver metastases.
25 e identified; two presented with synchronous liver metastases.
26 erapy in patients presenting with colorectal liver metastases.
27 construction algorithms for the detection of liver metastases.
28 ased the rate of resection for IU colorectal liver metastases.
29 atocellular carcinomas, were also mutated in liver metastases.
30 y-only, 41% primary + lymph node, and 7% had liver metastases.
31 a large majority of metachronous colorectal liver metastases.
32 c targets in the prevention and treatment of liver metastases.
33 regressions in primary tumors and colorectal liver metastases.
34 a new therapeutic target in the treatment of liver metastases.
35 portant effect in the immune surveillance of liver metastases.
36 shed as a prognostic indicator in colorectal liver metastases.
37 ingly used to treat patients with colorectal liver metastases.
38 alterations in pancreatic primary tumors and liver metastases.
39 SCs to form a premetastatic niche to promote liver metastases.
40 lications of radioembolization of colorectal liver metastases.
41 loid cells can be used to target established liver metastases.
42 e of invasive tumors and no apparent lung or liver metastases.
43 to liver endothelial cells and formation of liver metastases.
44 premetastatic niche that ultimately promoted liver metastases.
45 ients with metastatic colorectal cancer with liver metastases.
46 patic peritoneal metastasis and hematogenous liver metastases.
47 vacizumab in patients with colorectal cancer liver metastases.
48 est (90)Y study for patients with colorectal liver metastases.
49 ue of hepatic USG for detecting asymptomatic liver metastases.
50 as reduced in CTC compared to tumor cells in liver metastases.
51 eived (90)Y radioembolization for colorectal liver metastases.
52 marker for metastatic activity of colorectal liver metastases.
53 glass microsphere treatments for colorectal liver metastases.
54 sed cell death in primary CTCL tumors and in liver metastases.
55 hepatocellular carcinoma and 2 patients with liver metastases (1 neuroendocrine, 1 colorectal) underw
57 mor (SS-group), (2) resection of synchronous liver metastases 3 to 12 months after resection of the p
58 ETHODS Forty-nine patients with unresectable liver metastases (53% previously treated with chemothera
59 with 473 procedures (139 HCC, 198 colorectal liver metastases, 61 neuroendocrine liver metastases, an
60 ion is also prevalent in human breast cancer liver metastases, a setting in which results with anti-a
61 erapy in patients with neuroendocrine tumors liver metastases; a lower pretreatment distribution volu
62 ersus nonanatomical resection for colorectal liver metastases, according to KRAS mutational status.
63 d systemic increases in TIMP1 developed more liver metastases after injections of pancreatic cancer c
64 % of patients with colorectal cancer develop liver metastases after resection of the primary tumor, a
65 ong with the proportion of mice with diffuse liver metastases, an effect ablated by coexpression of N
67 ning to the role of surgery in patients with liver metastases and concomitant extrahepatic disease.
68 increasing evidence to support resection of liver metastases and concurrent EHD in selected patients
69 increasing evidence to support resection of liver metastases and concurrent EHD in selected patients
70 term survival is possible after resection of liver metastases and concurrent EHD, but true cure is ra
71 term survival is possible after resection of liver metastases and concurrent EHD, but true cure is ra
72 urgery may prove to be effective at reducing liver metastases and increasing the survival benefit of
73 ted with a high rate of somatic mutations in liver metastases and inferior outcomes after hepatectomy
75 T-PCR and immunohistochemistry in colorectal liver metastases and nontumorous-adjacent liver parenchy
76 d: (1) simultaneous resection of synchronous liver metastases and primary tumor (SS-group), (2) resec
77 number dramatically during establishment of liver metastases and were recruited from bone marrow by
79 ine patients with NETs (41 patients with 162 liver metastases, and 18 control subjects with no liver
80 lorectal liver metastases, 61 neuroendocrine liver metastases, and 75 other) for a total of 875 tumor
81 vs 1), age (<50 vs >/=50 years), presence of liver metastases, and histopathological grade (2 vs 3).
82 response to neoadjuvant chemotherapy in the liver metastases, and inhibition of this protein at both
84 pcCRC remained after adjusting for age, PS, liver metastases, and other factors (OS: HR = 1.3, P < .
86 d in purine metabolism, were detected in 4/5 liver metastases, and the same four liver metastases sha
88 growth inhibition (TGI) = 76% at 35 mg/kg), liver metastases, and tumor blood vessels compared with
89 atients with metastatic disease will develop liver metastases, and, therefore, the control of liver m
93 reason for this unfavorable outcome is that liver metastases are poorly vascularized, limiting the a
94 d immediately after percutaneous ablation of liver metastases are predictors of local treatment failu
95 ent results reveal that NKT cells exacerbate liver metastases arising from intraocular melanomas.
96 cells, especially type I NKT cells, enhanced liver metastases arising from intraocular melanomas.
99 CL5-promoter activation within the stroma of liver metastases as evidenced by tumor-selective iodide
100 ur knowledge), robust MRI detection of early liver metastases as small as approximately 0.24 mm in di
102 ew the existing approaches to neuroendocrine liver metastases, assess the evidence on which managemen
104 of perioperative chemotherapy for colorectal liver metastases, associations between specific agents a
105 between observers 1 and 2 for characterizing liver metastases at per-lesion analysis (kappa coefficie
108 pproximately 75-80% of patients present with liver metastases at the time of their diagnosis, and 20%
111 ected patients with nonresectable colorectal liver metastases benefit from liver transplantation and
113 ulted not only in a higher detection rate of liver metastases but also in a significantly higher lesi
114 for preventing the initial establishment of liver metastases but has limited application for use in
115 n be recommended for downsizing unresectable liver metastases, but not for resectable lesions, for wh
118 e a metastatic CRC mouse model and show that liver metastases can manifest without a lymph node metas
121 ong-term survival to selected patients whose liver metastases cannot be removed in a single procedure
124 t bevacizumab before resection of colorectal liver metastases (CLM) and to identify predictors of the
125 We hypothesized that metachronous colorectal liver metastases (CLM) have different biology after fail
126 f postoperative complications for colorectal liver metastases (CLM) in the era of RAS mutation analys
127 stage resection (TSR) of advanced colorectal liver metastases (CLM) may be the result of selection of
132 56.8 y; range, 35-79 y) for the treatment of liver metastases (colorectal, n = 23; breast, n = 1; and
136 PGE2 had increased numbers of cecal CSCs and liver metastases compared with controls after intracecal
138 luate outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic dise
139 luate outcomes after resection of colorectal liver metastases (CRLM) and concurrent extrahepatic dise
141 ent of patients with simultaneous colorectal liver metastases (CRLM) includes liver-directed chemothe
142 ern multidisciplinary therapy for colorectal liver metastases (CRLM) is associated with significant m
143 in the treatment of patients with colorectal liver metastases (CRLM) is the Kirsten rat sarcoma viral
144 y-nine patients with unresectable colorectal liver metastases (CRLM) were included in a single-instit
150 lorectal cancer (CRC), it is unknown whether liver metastases derive from cancer cells that first col
151 established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte-media
155 ssue from both primary colorectal tumour and liver metastases from 17 patients was subjected to prote
156 ho underwent primary resection of colorectal liver metastases from 2 major hepatobiliary units in the
157 rs, a shift in indications toward colorectal liver metastases from 53% to 77% and a reverse trend in
159 Clinically, immunohistochemical analysis of liver metastases from chemotherapy-naive colon cancer pa
160 rs) who underwent radioembolization to treat liver metastases from colorectal adenocarcinoma between
163 pected of having hepatocellular carcinoma or liver metastases from colorectal cancer and were schedul
164 resectability in patients with unresectable liver metastases from colorectal cancer treated with hep
165 ring preoperative treatment of patients with liver metastases from colorectal cancer, and its predict
166 the treatment of patients with unresectable liver metastases from colorectal cancer, demonstrating a
167 cle of treatment in patients with resectable liver metastases from colorectal cancer, within a phase
169 ve for the detection and characterization of liver metastases from NETs than T2-weighted FSE and dyna
170 unexpectedly caused a remarkable increase in liver metastases from neuroblastoma and breast cancer ce
174 ished PET response criteria in patients with liver metastases from pancreatic cancer after treatment
179 ncreasing use of chemotherapy for colorectal liver metastases has raised awareness of the potential h
181 athologic findings of core liver biopsies of liver metastases identified by needle localization in a
182 then, she had been treated with resection of liver metastases in 2009 and 2010, palliative combinatio
184 6 to 82 years), hemoglobin < 10 g/dL in 17%, liver metastases in 30%, median time from prior chemothe
185 icantly reduced whole body, lung, kidney and liver metastases in an experimental metastases mouse mod
186 otherapy and surgery for operable colorectal liver metastases in KRAS exon 2 wild-type patients resul
189 ssociated with CTC shedding from established liver metastases in the training and validation cohorts.
190 (Arp2/3) is required for vessel co-option in liver metastases in vivo and that, in this setting, comb
192 Intraarterial therapy options for colorectal liver metastases include chemoinfusion via a hepatic art
194 a mouse model with preestablished CD46(high) liver metastases, intravenous injection of Ad5/35++ resu
198 er curatively intended surgery of colorectal liver metastases is feasible and may significantly impro
199 atic resection of colorectal carcinoma (CRC) liver metastases is increasing, but evidence for the imp
200 ents with colorectal cancer with synchronous liver metastases is possible but is associated with a wi
202 ot be withheld from patients with colorectal liver metastases lacking intratumoral (99m)Tc-MAA accumu
203 in already established, experimental, murine liver metastases led to diminished metastatic growth.
204 r curatively intended surgery for colorectal liver metastases, liver recurrences occur in more than 6
205 who underwent liver transplantation (LT) for liver metastases (LM) from neuroendocrine tumors (NET) o
206 udy aimed to assess the prognostic impact of liver metastases (LM) in patients with colorectal perito
208 metastases vs as suppressor in prostate and liver metastases) may eventually help us to develop bett
209 -six patients with a total of 435 colorectal liver metastases (mean number of lesions +/- SD, 6.6 +/-
211 t cancer liver metastases, n = 7; colorectal liver metastases, n = 5; hepatocellular carcinoma, n = 8
212 ectable advanced liver tumors (breast cancer liver metastases, n = 7; colorectal liver metastases, n
213 ents with multifocal, bilobar neuroendocrine liver metastases (NELM) after the first transarterial ch
214 : hepatocellular carcinoma (HCC), colorectal liver metastases, neuroendocrine liver metastases, and o
215 cancer (WHO performance status 0 or 1) with liver metastases not suitable for curative resection or
216 ns of 79 colorectal tumors and 23 associated liver metastases, obtained from 2 hospitals in Spain.
217 patients with unresectable, chemorefractory liver metastases of any origin were enrolled in this pha
219 ly, an analogous myeloid subset was found in liver metastases of some colorectal cancer patients.
220 growing in the liver in vivo and a subset of liver metastases of uveal melanoma patients express acti
221 sequencing identified mutations enriched in liver metastases of various cancers, including Notch pat
222 laparoscopic liver resection, for colorectal liver metastases, offers significant lower morbidity, an
224 ls with tumor-conditioned myeloid cells from liver metastases or myeloid cell conditioned media down-
227 ed into either the murine spleen to generate liver metastases or tail vein to generate lung metastase
228 with non-small cell lung cancer, colorectal liver metastases, or metastatic melanoma who were scanne
230 lizing antibody to mice bearing experimental liver metastases phenocopied neutrophil depletion by red
232 diameter of less than 8 cm for the 2 largest liver metastases predicted time to intrahepatic progress
233 esis, GCLC, becomes overexpressed in patient liver metastases, promotes cell survival under hypoxic a
234 liver parenchyma adjacent to the synchronous liver metastases provides an angiogenic prosperous envir
235 roups of patients, together with more than 3 liver metastases, R1 resection, and extrahepatic disease
236 o the significantly higher detection rate of liver metastases rather than tumor differentiation grade
238 tients with colorectal carcinoma and bilobar liver metastases received whole-liver radioembolization
239 m study, 56 patients were enrolled, all with liver metastases refractory to systemic therapy and inel
242 r "radioembolization" and "colorectal cancer liver metastases." Results were described separately for
243 d in 4/5 liver metastases, and the same four liver metastases shared mutations in 32 genes, including
245 margin achieved in patients with colorectal liver metastases should now be considered the standard o
246 Pathway analyses of all mutated genes in liver metastases showed aberrant tumor necrosis factor a
248 not granulocytes, isolated from experimental liver metastases stimulated migration and invasion of MC
249 RC) can be accompanied by rapid outgrowth of liver metastases, suggesting a role for angiogenesis.
250 on of metastatic signature miRs similarly to liver metastases, suggesting their involvement in adapti
251 % of salvage patients with colorectal cancer liver metastases survive more than 12 mo after treatment
252 f (18)F-FLT may limit utility for imaging of liver metastases.Targeting angiogenesis has had some suc
253 venous injection of LV12 cells produced more liver metastases than QRsP-11 cells, whereas the inciden
254 transfected with CXCR4 siRNA produced fewer liver metastases than untreated uveal melanoma cells or
257 era of effective chemotherapy for colorectal liver metastases, the association between surgical margi
259 Unresectable chemorefractory colon cancer liver metastases treated with (90)Y radioembolization in
260 f a large cohort of patients with colorectal liver metastases treated with (90)Y radioembolization us
262 of 82 patients with unresectable colorectal liver metastases treated with bevacizumab-containing che
264 microenvironment of either primary tumors or liver metastases triggered regression of established tum
267 ean: 2.2 cm +/- 1.1) metachronous colorectal liver metastases underwent ultrasonography-guided percut
268 metastases, and 18 control subjects with no liver metastases) underwent MR imaging that included DW,
269 rom explant cultures of CRC patients-derived liver metastases was associated with response to OXA + C
270 in the inhibition of liver NK resistance to liver metastases was determined by in vivo and in vitro
273 stases, whereas progression of nonresectable liver metastases was observed in the chemotherapy group.
275 CXCR4 siRNA transfection on the formation of liver metastases was tested by injecting transfected mel
276 low passage cultures from primary tumors and liver metastases we show that ATM loss accelerates Kras-
278 years; range 43.6-66.3), with neuroendocrine liver metastases were analyzed by means of distributed p
279 ING, AND PATIENTS: A total of 234 colorectal liver metastases were analyzed from 50 patients who unde
280 tratumoral (99m)Tc-MAA uptake was rated, and liver metastases were classified according to changes in
282 gnosed with metastatic disease in 2009, when liver metastases were found 1 year after the primary tre
285 patients treated with liver embolization for liver metastases were found, and similar results were de
287 ctable or suboptimally resectable colorectal liver metastases were randomised in a 1:1 ratio to recei
288 curative resection of at least 4 colorectal liver metastases, were selected from a prospective datab
289 cells demonstrated significant reduction in liver metastases when treated with N(1)-(3-aminopropyl)-
290 or bone metastases, distant lymph nodes, and liver metastases, whereas CT was more sensitive for lung
291 Food and Drug Administration for colorectal liver metastases, whereas institutional review board app
292 in a syngeneic tumor model resulted in fewer liver metastases, whereas PHD3 knockdown induced tumor s
293 EGFR-2 neutralization had no effect on RenCa liver metastases, whereas VEGFR-1 neutralization decreas
294 ys containing samples from CRC patients with liver metastases who had undergone hepatic resection.
295 ated the second hepatectomy in patients with liver metastases who required a 2-stage hepatectomy.
297 However, colony size was greatly reduced in liver metastases with decreased invasion into adjacent t
298 clinical benefit in patients with colorectal liver metastases with liver-dominant disease after chemo
299 ge of the biological phenotype of colorectal liver metastases would be invaluable to inform clinical
300 , chemotherapy type (vinflunine vs taxanes), liver metastases (yes vs no), and number of prognostic f
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。